ReviewJournal of medical case reports2026
Long-term survival with nivolumab in a patient with renal cell carcinoma: a case report and review of the literature.
Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapy has established itself as the standard treatment for advanced renal cell carcinoma (RCC), being used as a primary option alongside tyrosine kinase inhibitors (TKIs) as well as in later lines of therapy. CASE PRESENTATION: We present the case of a 67-year-old man from Latin America who experienced anemia and fatigue. A physical examination indicated tenderness in the left flank. An abdominal CT scan revealed a mass measuring 60 × 44 mm in the left kidney, while a chest CT displayed multiple nodules in both lungs. The clinical assessment led to a diagnosis of stage IV renal cell carcinoma (T1bN0M1). The patient had cytoreductive nephrectomy performed, followed by 25 months of sunitinib treatment. After the disease progressed, he was treated with everolimus, an mTOR inhibitor, but showed limited response. He then started third-line therapy with nivolumab, an immune checkpoint inhibitor (ICI), achieving a complete response after 48 months of treatment. He remains free of disease to this day.
conclusionsWe present a review of existing literature regarding the application of immunotherapy in this context, focusing on the timing and length of treatment for patients who have shown a clinical response, along with the possible advantages of maintaining immunotherapy treatment even after disease progression. Further research is essential to establish the most effective treatment duration and to pinpoint predictive biomarkers and criteria for selecting patients for tailored therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.